Start up. Grow up. Succeed.

News 2018

BioNTech and the University of Pennsylvania Enter into Strategic Research Collaboration to Develop mRNA Vaccine Candidates Against Various Infectious Diseases

New research program between BioNTech and the University of Pennsylvania Joining forces to advance mRNA-based vaccine development for ten infectious disease indications Further step to rapidly expand BioNTech’s new infectious disease franchise Mainz,...

VAXIMM Announces Regional Development and Commercialization Agreement with China Medical System Holdings

CMS gains exclusive rights to current VAXIMM pipeline and option for future programs for China and other Asian countries, ex-Japan VAXIMM to receive potential development and commercial milestone payments plus royalties on sales CMS to make an equity inves...

BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA‐based Vaccines for Prevention of Influenza

BioNTech will receive $120 million in upfront, equity and near‐term research payments from Pfizer and will be eligible to receive up to $305 million in potential development, regulatory and commercial milestone payments and up to double‐digit royalties P...

BioNTech and Genevant Sciences Sign Strategic mRNA‐Focused Partnership in Rare Diseases

Partnership combines Genevant’s industry‐leading delivery technology and BioNTech’s cutting‐edge mRNA drug discovery platform to develop best‐in‐class therapeutics BioNTech and Genevant will develop five products for rare diseases with h...

BioNTech Appoints Dr. Özlem Türeci as Chief Medical Officer

Mainz, Germany, May 29, 2018 – BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced the appointment of Özlem Türeci, M.D., as Chief Medical Officer, effective June 1, 2018. D...

Immunic Reports Start of Enrollment into Clinical Phase 2 Study with IMU-838 in Patients with Ulcerative Colitis

First patient with ulcerative colitis entered the ‘CALDOSE-1’ trial with Immunic’s oralinvestigational drug IMU-838, a best-in-class DHODH inhibitor Multiple sites have already been initiated in the US and first patient has been enrolled ...

Prof. Ugur Sahin receives prestigious EUROPEAN RESEARCH COUNCIL (ERC) ADVANCED GRANT for personalized cancer vaccines

Mainz, Germany, April 18, 2018 – Ugur Sahin, Scientific Director at TRON, has been awarded one of the prestigious ERC Advanced Grants 2017 for his project ‘SUMMIT - Stepping Up mRNA Mutanome Immunotherapy’, totaling 2.5 Million Euros over 5 y...

MAB Discovery GmbH - Cullinan Oncology and MAB Discovery Announce Collaboration to Develop Novel Antibody-Based Therapeutics

Cullinan Oncology and MAB Discovery Announce Collaboration to Develop Novel Antibody-Based Therapeutics CAMBRIDGE, Mass. USA, and NEURIED, Germany, February 20, 2018: CullinanOncology, LLC and MAB Discovery GmbH (MABD), announced today the init...

Pieris Pharmaceuticals to Present at the RBC Capital Markets 2018 Global Healthcare Conference

Pieris Pharmaceuticals to Present at the RBC Capital Markets 2018 Global Healthcare Conference Download PDF BOSTON, MA -- (Marketwired) -- 02/19/18 -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biot...

Pieris Pharmaceuticals Announces Closing of Public Offering and Exercise of Underwriters' Option to Purchase Additional Shares

Pieris Pharmaceuticals Announces Closing of Public Offering and Exercise of Underwriters' Option to Purchase Additional Shares Download PDF BOSTON, MA -- (Marketwired) -- 02/16/18 -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnol...

EIT Health Spain welcome BIST and Ferrer as new partners

15th February 2018   EIT Health Spain welcomes the Barcelona Institute of Science and Technology (BIST) as a new core partner and Ferrer as a new associate partner. The Barcelona Institute of Science and Technology (BIST) is a scientific initiative o...

Pieris Pharmaceuticals Announces Public Offering of Common Stock

Pieris Pharmaceuticals Announces Public Offering of Common Stock BOSTON, MA -- (Marketwired) -- 02/13/18 -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticali...

BioNTech Secures USD 270 Million in Series A Financing

Mainz, Germany, January 4, 2018 BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced it has completed a USD 270 million Series A round of financing. The Company previously completed a seed round...

Immunic AG - FDA approves IND for Immunic Therapeutics’ IMU-838 to proceed with Phase 2 study in ulcerative colitis

FDA approves IND for Immunic Therapeutics’ IMU-838 to proceed with Phase 2 study in ulcerative colitis FDA has granted IND approval for Immunic’s oral investigational drug IMU-838 Active IND allows Immunic to proceed with Phase 2 clinica...